Short answer
Verastem, Inc. (VSTM) filed an 8-K current report with the SEC on June 17, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Positive updated RAMP 205 results for avutometinib plus defactinib in first-line metastatic pancreatic ductal carcinoma.
Verastem, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive updated RAMP 205 results for avutometinib plus defactinib in first-line metastatic pancreatic ductal carcinoma
- Combination evaluated alongside standard-of-care chemotherapy in mPDAC
- Clinical update supports Verastem’s pancreatic cancer development strategy
- Full efficacy and safety details available in Exhibit 99.1
Item 8.01 · Other Events
- RAMP 205 RP2D cohort showed 86% six-month overall survival and 68% six-month progression-free survival in first-line mPDAC
- Confirmed objective response rate reached 52%, with tumor shrinkage in 83% of patients
- Nine patients remained on treatment at 9.8-month median follow-up, supporting continued clinical activity
- No new safety signals observed, reducing near-term tolerability concerns
- TARGET-D 201 Phase 2 registration-directed trial initiated for VS-7375 in KRAS G12D-mutated second-line mPDAC at 900 mg daily
Item EX-99.1 · Exhibit EX-99.1
- RAMP 205 interim data: 6-month overall survival 86%, progression-free survival 68%, and confirmed response rate 52% in 29 patients
- 90% presented with Stage IV disease; 83% experienced tumor shrinkage, supporting activity in a highly aggressive setting
- Nine patients remained on treatment; median follow-up 9.8 months, with survival data still maturing
- No new safety signals reported, supporting continued development with gemcitabine and nab-paclitaxel
- Single-arm Phase 1b/2a results remain preliminary; final survival data and future development decisions are key catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Verastem, Inc. 8-K filings
Get the next VSTM 8-K as it lands
Follow VSTM for push alerts, or ask the research agent what this filing means.